Doxycycyline
PreclinicalSmall molecule
Doxycycyline is one of 7 small molecule programs targeting Syphilis. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
8 competitors in Syphilis
#DrugCompanyPhaseTrials
1Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Rocephin
CConrado Roberto Hoffmann Filho
Approved
Amoxil
GGlobal Antibiotics Research and Development Partnership
Phase 3
Suprax
WWyeth-Lederle Vaccines
Approved
Doxycycline for 14 Days
UUniversity of Washington
Phase 2
Ceftriaxone Sodium
PfizerPreclinical
Doxycycyline
LLos Angeles LGBT Center
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Doxycycyline. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- LLos Angeles LGBT Center